A retrospective study for predict the response to anti-PD-1 treatment in metastatic renal cell carcinoma patients, by evaluating change of serum C-reactive protein levels during molecular-targeted treatments
Latest Information Update: 16 Jun 2020
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
Most Recent Events
- 16 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology